These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 21832868)

  • 21. [Bacillus Calmette-Guerin intravesical instillation treatment for carcinoma in situ of the bladder. Gifu BCG Instillation Therapy Research Group].
    Nishino Y; Yasuda M; Yokoi S; Ehara H; Yamamoto N; Takahashi Y; Ishihara S; Deguchi T; Kawada Y; Takeda A; Sakai S; Takeuchi T; Taniguchi M; Minoshima K; Hamamoto Y; Kanimoto Y; Nakano M; Fujihiro S; Nezasa S; Matsuda T; Nagatani Y; Maeda S; Tamaki M; Saito A; Komeda H
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1869-73. PubMed ID: 10560414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate.
    Palou J; Xavier B; Laguna P; Montlleó M; Vicente J
    Urology; 1996 Apr; 47(4):482-4. PubMed ID: 8638354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results.
    Losa A; Hurle R; Lembo A
    J Urol; 2000 Jan; 163(1):68-71; discussion 71-2. PubMed ID: 10604316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcome of upper urinary tract carcinoma in situ: effectiveness of nephroureterectomy versus bacillus Calmette-Guérin therapy.
    Kojima Y; Tozawa K; Kawai N; Sasaki S; Hayashi Y; Kohri K
    Int J Urol; 2006 Apr; 13(4):340-4. PubMed ID: 16734847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.
    Lamm DL; Blumenstein BA; Crawford ED; Montie JE; Scardino P; Grossman HB; Stanisic TH; Smith JA; Sullivan J; Sarosdy MF
    N Engl J Med; 1991 Oct; 325(17):1205-9. PubMed ID: 1922207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radical nephroureterectomy as initial treatment for carcinoma in situ of upper urinary tract.
    Yuasa T; Tsuchiya N; Narita S; Inoue T; Saito M; Kumazawa T; Horikawa Y; Matsuura S; Satoh S; Nanjo H; Habuchi T
    Urology; 2006 Nov; 68(5):972-5. PubMed ID: 17095072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Additional bacillus Calmette-Guérin therapy for recurrent transitional cell carcinoma after an initial complete response.
    Bui TT; Schellhammer PF
    Urology; 1997 May; 49(5):687-90; discussion 690-1. PubMed ID: 9145971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation.
    Ovesen H; Horn T; Steven K
    J Urol; 1997 May; 157(5):1655-9. PubMed ID: 9112499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
    Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
    Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Radical cystectomy for superficial tumors in the BCG era].
    Huguet Pérez J; Palou J; Millán Rodríguez F; Villavicencio Mavrich H; Rodríguez JV
    Arch Esp Urol; 2002; 55(1):50-6. PubMed ID: 11957752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative study of oncologic outcome of laparoscopic nephroureterectomy and standard nephroureterectomy for upper urinary tract transitional cell carcinoma.
    Manabe D; Saika T; Ebara S; Uehara S; Nagai A; Fujita R; Irie S; Yamada D; Tsushima T; Nasu Y; Kumon H;
    Urology; 2007 Mar; 69(3):457-61. PubMed ID: 17382144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Gúerin immunotherapy.
    Gofrit ON; Pode D; Pizov G; Zorn KC; Katz R; Duvdevani M; Shapiro A
    Urol Oncol; 2009; 27(3):258-62. PubMed ID: 18440839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy.
    Hurle R; Losa A; Ranieri A; Graziotti P; Lembo A
    J Urol; 1996 Nov; 156(5):1602-5. PubMed ID: 8863547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.
    Boorjian SA; Zhu F; Herr HW
    BJU Int; 2010 Aug; 106(3):357-61. PubMed ID: 20002665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
    Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
    J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Independent predictors of contralateral metachronous upper urinary tract transitional cell carcinoma after nephroureterectomy: multi-institutional dataset from three European centers.
    Novara G; De Marco V; Dalpiaz O; Galfano A; Bouygues V; Gardiman M; Martignoni G; Patard JJ; Artibani W; Ficarra V
    Int J Urol; 2009 Feb; 16(2):187-91. PubMed ID: 19054165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.